Lilly Gets FDA Priority Review Designation For Emgality Injection - Quick Facts

Eli Lilly and Co. (LLY) said Tuesday that the U.S. Food and Drug Administration has granted Priority Review for its supplemental Biologics License Application or sBLA for Emgality or galcanezumab-gnlm injection for the preventive treatment of episodic cluster headache in adults.

from RTT - Biotech https://ift.tt/2C5AEe2
via IFTTT